GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Days Sales Outstanding

Sumitomo Pharma Co (Sumitomo Pharma Co) Days Sales Outstanding : 102.95 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Sumitomo Pharma Co Days Sales Outstanding?

Sumitomo Pharma Co's average Accounts Receivable for the three months ended in Dec. 2023 was $646 Mil. Sumitomo Pharma Co's Revenue for the three months ended in Dec. 2023 was $572 Mil. Hence, Sumitomo Pharma Co's Days Sales Outstanding for the three months ended in Dec. 2023 was 102.95.

The historical rank and industry rank for Sumitomo Pharma Co's Days Sales Outstanding or its related term are showing as below:

DNPUF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.24   Med: 95.69   Max: 117.01
Current: 117.01

During the past 13 years, Sumitomo Pharma Co's highest Days Sales Outstanding was 117.01. The lowest was 81.24. And the median was 95.69.

DNPUF's Days Sales Outstanding is ranked worse than
81.42% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs DNPUF: 117.01

Sumitomo Pharma Co's Days Sales Outstanding declined from Dec. 2022 (103.56) to Dec. 2023 (102.95).

Sumitomo Pharma Co Days Sales Outstanding Historical Data

The historical data trend for Sumitomo Pharma Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Days Sales Outstanding Chart

Sumitomo Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.25 94.34 96.09 97.64 87.57

Sumitomo Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.56 116.80 118.88 115.05 102.95

Competitive Comparison of Sumitomo Pharma Co's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Days Sales Outstanding falls into.


Sumitomo Pharma Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Sumitomo Pharma Co's Days Sales Outstanding for the fiscal year that ended in Mar. 2023 is calculated as

Days Sales Outstanding (A: Mar. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Mar. 2022 ) + Accounts Receivable (A: Mar. 2023 )) / count ) / Revenue (A: Mar. 2023 )*Days in Period
=( (1276.862 + 717.529) / 2 ) / 4156.263*365
=997.1955 / 4156.263*365
=87.57

Sumitomo Pharma Co's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (635.071 + 656.091) / 2 ) / 572.199*365 / 4
=645.581 / 572.199*365 / 4
=102.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co  (OTCPK:DNPUF) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Sumitomo Pharma Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (OTCPK:DNPUF) » Definitions » Days Sales Outstanding
Comparable Companies
TSE:4540 TSE:4887 TSE:4547 TSE:4521 TSE:4534 TSE:4553 TSE:4569 TSE:4551 TSE:4559 TSE:4886 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
4506:Japan DPM:Germany
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Website
https://www.sumitomo-pharma.com
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.